
|Articles|October 27, 2008
Dusa Pharmaceuticals abandons Levulan PDT
Wilmington, Mass. - Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results.
Advertisement
Wilmington, Mass.
- Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results, Reuters reports.
The treatment combination, called Levulan PDT, is approved for the treatment of actinic keratoses of the face and scalp. It is also used off-label to treat photodamage.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
3
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
4
Practical Approaches to Managing Atopic Dermatitis With Topical Therapies
5

















